Autoantibodies with Mimicking Specificity Detected by the Dilution Technique in Patients with Warm Autoantibodies

Min-Joong Jang, M.D.1,*, Duck Cho, M.D.1,*, Kyoung-Un Park, M.D.2, Mark Harris Yazer, M.D.3, Myung-Geun Shin, M.D.1, Jong-Hee Shin, M.D.1, Soon-Pal Suh, M.D.1, and Dong-Wook Ryang, M.D.1

Department of Laboratory Medicine1, Chonnam National University Medical School, Gwangju; Department of Laboratory Medicine2, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Pathology3, University of Pittsburgh, Pittsburgh, USA

Background: The aim of this study was to investigate the frequency of autoantibodies with mimicking specificity by using the dilution technique, to assess the usefulness of the combination of the dilution technique and red blood cell (RBC) phenotyping, and to establish a pre-transfusion testing algorithm in patients with warm autoantibodies.

Methods: Serum samples from 71 patients with warm autoantibodies were tested using the dilution technique. Among them, 25 samples were adsorbed with allogeneic ZZAP (a combination of dithiothreitol and enzyme) or polyethylene glycol (PEG) and their RBC phenotypes were determined. Thirty-nine patients were transfused with our pre-transfusion testing algorithm using a combination of dilution technique and RBC phenotyping.

Results: Autoantibodies with mimicking specificity were detected by the dilution technique in 26.8% (19/71) of the patients and most of them were directed against Rh system antigens. The agreement of the results obtained with the dilution technique in combination with RBC phenotyping and those from ZZAP or PEG adsorption was 100% (18/18) in patients who have autoantibodies with mimicking specificity and/or alloantibodies. No clinical symptoms indicating severe acute or delayed hemolytic transfusion reactions were reported in the 39 patients transfused with our pre-transfusion testing algorithm.

Conclusions: Autoantibodies with mimicking specificity detected by the dilution technique in patients with warm autoantibodies are relatively frequent, can be discriminated from alloantibodies by employing a combination of dilution technique and RBC phenotyping, and might not appear to cause severe acute or delayed hemolytic transfusion reactions.

Key Words: Autoantibody, Dilution technique, Mimicking specificity

INTRODUCTION

In the pre-transfusion testing of patients whose sera contain warm autoantibodies, it must be determined whether alloantibodies, which could be masked by the autoantibodies, are also present [1]. To date, application of the dilution technique on patients’ sera and adsorption techniques employing polyethylene glycol (PEG) and ZZAP (a combination of dithiothreitol and enzyme) have been developed [2-4]. Among them, it has been reported that the most reliable methods are the adsorption procedures using allogeneic or autologous red blood cells (RBCs) treated with enzymes or ZZAP reagent [3, 5]. However, these methods are time consuming [3].

In contrast to the ZZAP method, the dilution technique is a simple procedure capable of detecting alloantibodies masked by autoantibodies [2]. Experimentally, it consists of testing di-
luted serum sample against a panel of RBC reagents. Although
dilution should be performed only when the alloantibody titer is
higher than the autoantibody titer, the dilution technique has
been used in some laboratories that do not have the capability
to perform the adsorption methods (e.g., ZZAP and PEG) [1].

In our hospital laboratory, the dilution technique has been
performed since 2009. In contrast to a previous report [6], a
high frequency of autoantibodies with mimicking blood group
specificity was detected with this technique.

Therefore, we investigated the frequency of the autoantibod-
ies with mimicking specificity by using the dilution technique on
serum samples from patients with warm autoantibodies, com-
pared the dilution technique with ZZAP or PEG adsorption
methods, and established the RBC transfusion workflow by us-
ing a combination of dilution technique and RBC phenotyping.

METHODS

1. Samples

Serum samples were selected among 54,848 patients who un-
derwent pre-transfusion investigations at the Chonnam National
University Hospital (Gwangju, Korea) and Chonnam National
University Hwasun Hospital (Jeollanam-do, Korea) between No-
vember 2009 and November 2011.

2. Serologic evaluation

Serologic techniques were performed according to the Ameri-
can Association of Blood Banks (AABB) standards [7]. We de-
termined the RBC phenotype of the patients at least three
months after the last transfusion by using the commercially
available phenotyping gel card RhD+Phenotype (DiaMed
GmbH, Cressier, Switzerland). In some patients, Rh phenotypes
were confirmed by determining the RBC phenotype after ZZAP
treatment or by using RHD and RHCE genotyping [8].

A warm autoantibody was defined as an antibody that reacts
at 37°C with antihuman globulin (AHG) and with the patient’s
own RBCs. In this study, the detection was carried out with the
entire panel of 11 RBC reagents by using the ID-DiaPanel sys-
tem (DiaMed GmbH). To confirm the presence of an autoanti-
body, a direct antiglobulin test (DAT) was also performed when
patients with suspected autoantibodies were identified. The DAT
was performed using the DC-Screening I gel card (DiaMed
GmbH). When a warm autoantibody was confirmed according
to the above-described criteria, we performed the dilution tech-
nique to reduce the titer of the autoantibodies, thereby allowing
the detection of any underlying alloantibodies.

3. Dilution technique and adsorption

We performed the dilution technique as previously described
[9]. Briefly, we diluted the serum samples in saline by perform-
ing 2-fold serial dilutions until a 1+ reaction was achieved in the
column agglutination method using LISS/Coombs card (DiaMed
GmbH) and ID-DiaCell I+II (DiaMed GmbH). Then, we per-
formed alloantibody identification by mixing the diluted serum
with the 11 RBC reagents on the panel by using the ID-DiaPanel
system.

Alloadsorption was performed as previously described to dis-
criminate between alloantibodies and autoantibodies with mim-
icking specificity [1]. Autoantibodies with mimicking specificity
were considered antibodies that display apparent antigen speci-
ficity and that do not maintain specificity following alloadsorption
[6].

RESULTS

1. Frequency and specificity of antibodies identified by the
dilution technique in patients with warm autoantibodies

From November 2009 to November 2011, pre-transfusion inves-
tigations were performed on 54,848 patients, of which 553 un-
derwent antibody identification testing by the gel column agglu-
tination method. Seventy-five patients with warm autoantibodies
were detected and the dilution technique combined with RBC
phenotyping was applied to the serum samples of 71 of those
patients to find alloantibodies and/or autoantibodies with mim-
icking specificity. Among those 71 patients, by using the combi-
nation of dilution technique and red cell phenotyping to dis-
criminate autoantibodies with mimicking specificity from possi-
bile alloantibodies, we found that 26.8% had autoantibodies with
mimicking specificity. Autoanti-C+e, autoanti-e, autoanti-E, au-
toanti-C, and autoanti-D were the most common mimicking
specificities in the order of detection rate. The specificities of the
antibodies in those 71 patients are listed in Table 1.

2. Comparison of the antibody specificities identified by the
dilution technique and adsorption

Of the 71 samples, 25 provided enough volume for further sero-
logic evaluation using ZZAP or PEG adsorptions to discriminate
the autoantibodies with mimicking specificity from the alloanti-
bodies. The dilution fold of the samples that resulted in a 1+ re-
action in the column agglutination method using the LISS/
Coombs card varied from 1:2 to 1:512. In patients who have au-
toantibodies with mimicking specificity and/or alloantibodies,
the agreement of the results obtained with the dilution tech-
Table 1. Antibody specificities of 71 patient serum samples containing warm autoantibodies as identified by the dilution technique

| Mimicking specificity\(^a\) | Possible true specificity |
|----------------------------|-------------------------|
| Anti-C+e (5)\(^1\)         | Anti-C+e (1)             |
| Anti-e (5)                 | Anti-E+c (6)             |
| Anti-E (3)                 | Anti-E (2)               |
| Anti-C (3)                 | Anti-D (1)               |
| Anti-D (1)                 | Anti-JK\(^+\)-unidentified (1) |
| Anti-E+unidentified (1)    |                          |
| Anti-C+unidentified\(^1\) (1) |                        |
| Unidentified (29)          |                          |
| None (12)                  |                          |

\(^a\)Mimicking specificity was assessed by the combination of dilution technique and RBC phenotyping; \(^1\)Numbers in parentheses indicate number of cases; \(^2\)The case was confirmed as alloantibody (unidentified antibody) with mimicking autoantibody (autoanti-C) in allogeneic ZZAP adsorption.

In our retrospective investigation, we transfused “least incompatible” RBCs to 17 patients who shows unidentified pattern in antibody identification test, 10 patients with warm autoantibodies without mimicking specificity detected in our study were completely removed by ZZAP or PEG alloadsorption. In patients with warm autoantibodies without mimicking specificity detected by the dilution technique, the adsorption methods did not identify any alloantibodies except in case 4, for which the warm autoantibodies might not have been completely adsorbed by ZZAP (Table 2).  

3. RBC transfusion workflow in patients with warm autoantibodies by using a combination of dilution technique and RBC phenotyping

In our retrospective investigation, we transfused “least incompatible” RBCs to 17 patients who shows unidentified pattern in antibody identification test, 10 patients with warm autoantibodies without mimicking specificity, and 5 patients with autoantibodies with mimicking specificity detected in our study were completely removed by ZZAP or PEG alloadsorption. In patients with warm autoantibodies without mimicking specificity detected by the dilution technique, the adsorption methods did not identify any alloantibodies except in case 4, for which the warm autoantibodies might not have been completely adsorbed by ZZAP (Table 2).  

In our hospital laboratory, the dilution technique has been performed since 2009. To the best of our knowledge, this is the first study to indicate that the detection of autoantibodies with mimicking specificity is relatively common, and to propose a simple screening method for the discrimination of autoantibodies with mimicking specificity from alloantibodies in patients with warm autoantibodies.  

There are more patients with warm autoantibodies having mimicking specificity than patients with both warm autoantibodies and alloantibodies. Furthermore, in our study, most of the autoantibodies with mimicking specificity proved to be directed against the Rh system antigens, such as C+e, e, C, and D, thereby making it very difficult to find compatible RBC units for the Korean people. Although they display apparent antigen specificity, our results suggest that many of the antibodies identified with the dilution technique were not true alloantibodies and the mimicking autoantibodies are commonly present in patients with warm autoantibodies.  

Mimicking autoantibodies were first described by Funderberg et al. [10] as autoantibodies having the “wrong” specificity, and are generally considered “not common” in routine blood bank serology [6]. To date, very few studies reporting the frequency and specificity of the autoantibodies with mimicking specificity were performed. Issitt et al. [11] reported that for 21.0% (29/138) of the patients with warm autoantibodies, partially adsorbed autoantibodies appeared mimicked alloantibodies in ZZAP adsorption method. Wheeler et al. [12] used alloadsorption and found that 12.0% (12/100) of the serum sample showing positive DAT contained mimicking autoantibodies. The frequencies reported in the previous reports are much lower than the frequency (26.8%) reported in this study. In addition, in our experiments, all the autoantibodies with mimicking specificity revealed by the dilution technique were completely removed by ZZAP or PEG alloadsorption. We suggest that the dilution technique makes the autoantibodies with mimicking specificities more detectable than do ZZAP or PEG adsorption, by producing non-specific partial adsorption of the warm autoantibodies.

It was proposed that since warm antibodies are continually adsorbed by the patient RBCs, it is likely that the amount of autoantibodies left in the serum is less than that of alloantibodies. Therefore, if the patient serum is diluted, the more concentrated
alloantibodies become more obvious [13]. Øyen et al. [2] reported that no clinically significant alloantibodies were missed by the serum dilution method compared to allogeneic adsorptions using the 1:5 dilution protocol. In contrast, Leger et al.

| Category (% of cases) | Case No. | Age (yr)/sex | Transfusion/Pregnancy history | Rh phenotype | Antibody specificity | Dilution technique (dilution fold) | ZZAP or PEG adsorption (method, N of adsorptions) | Disease history |
|-----------------------|----------|--------------|-------------------------------|--------------|---------------------|-----------------------------------|--------------------------------|---------------|
| Warm autoantibodies without mimicking specificity (28%) | 1        | 80/M         | No/No                         | cdEe         | None (not checked)  | None (ZZAP, 1)                   | CRF               |
|                       | 2        | 58/M         | No/No                         | CcDDe        | None (4×)           | None (ZZAP, 1)                   | APS               |
|                       | 3        | 66/F         | No/Yes                        | CcDDe        | None (16×)          | None (PEG, 2)                    | HA                |
|                       | 4        | 16/M         | No/No                         | CcDDe        | None (512×)         | Unidentified (ZZAP, 6)           | AIHA              |
|                       | 5        | 22/M         | Yes/No                        | CDe          | None (8×)           | None (ZZAP, 3)                   | AA                |
|                       | 6        | 62/F         | Yes/Yes                       | CcDDe        | Unidentified (4×)   | None (ZZAP, 2)                   | APS               |
|                       | 7        | 54/F         | No/Yes                        | CcDe         | Unidentified (not checked) | None (ZZAP, 2)                   | PTC               |
| Warm autoantibodies and alloantibodies (16%) | 8        | 70/F         | Yes/Yes                       | cDe          | Anti-C+e (2×)       | Anti-C+e (PEG, 2)                | MDS, RCMD         |
|                       | 9        | 30/F         | No/No                         | cDe          | Anti-C (1×)         | Not tested                       | Calcaneus fracture |
|                       | 10       | 38/F         | Yes/Yes                       | CDe          | Anti-E (2×)         | Anti-E (ZZAP, 1)                 | SLE               |
|                       | 11       | 62/F         | No/Yes                        | CDe          | Anti-E (4×)         | Anti-E (ZZAP, 1)                 | Cervical cancer    |
| Warm autoantibodies with mimicking specificity and alloantibodies (4%) | 12       | 77/F         | Yes/Yes                       | CDe          | Anti-C + unidentified Ab (2×) | Unidentified Ab (ZZAP, 1) | Evan’s syndrome |
| Warm autoantibodies with mimicking specificity (52%) | 13       | 32/F         | Yes/Yes                       | CcDDe¹       | Anti-C+e (8×)       | None (ZZAP, 1)                   | AIHA, CML         |
|                       | 14       | 60/F         | No/Yes                        | CcDDe¹       | Anti-C+e (512×)     | None (ZZAP, 2)                   | AIHA, PTC         |
|                       | 15       | 6/M          | Yes/No                        | CcDDe¹       | Anti-C+e (not checked) | None (ZZAP, 1)                   | Autoimmune disease |
|                       | 16       | 74/M         | No/No                         | CcDDe        | Anti-C+e (2×)       | None (ZZAP, 2)                   | T-cell lymphoma   |
|                       | 17       | 7/F          | Yes/No                        | CcDDe        | Anti-C+e (2×)       | None (ZZAP, 3)                   | Osteosarcoma       |
|                       | 18       | 24/F         | Yes/Yes                       | CcDDe        | Anti-E+e (8×)       | None (ZZAP, 1)                   | SLE, AIHA         |
|                       | 19       | 69/M         | Yes/No                        | CcDDe¹       | Anti-e (not checked) | None (ZZAP, 1)                   | MDS, RCMD         |
|                       | 20       | 23/M         | No/No                         | CDe¹         | Anti-e (2×)         | None (ZZAP, 2)                   | AIHA, APS         |
|                       | 21       | 17/F         | No/No                         | cDe          | Anti-e (16×)        | Unidentified (ZZAP, 1)           | AIHA, SLE         |
|                       | 22       | 81/F         | No/Yes                        | CDe¹         | Anti-e (4×)         | None (PEG, 3)                    | Spondylitis       |
|                       | 23       | 63/M         | No/No                         | CcDDe        | Anti-C (4×)         | None (ZZAP, 1)                   | Castleman’s disease |
|                       | 24       | 17/F         | No/No                         | CcDDe        | Anti-C (4×)         | None (ZZAP, 1)                   | Evan’s syndrome   |
|                       | 25       | 69/F         | No/Yes                        | CcDDe        | Anti-E+unidentified Ab (2×) | None (ZZAP, 4)                   | HLH               |

*Antibody specificity was confirmed about six months later without adsorption procedures; †Rh phenotype was confirmed by RHCE genotyping.

Abbreviations: AA, aplastic anemia; AIHA, autoimmune hemolytic anemia; APS, antiphospholipid syndrome; CRF, chronic renal failure; HA, hemolytic anemia; MDS, myelodysplastic syndrome; RCMD, refractory cytopenia with multilineage dysplasia; HLH, hemophagocytic lymphohistiocytosis; PTC, papillary thyroid cancer; SLE, systemic lupus erythematosus.
[1] reported that 10 potentially clinically significant alloantibodies were not identified because they were masked by the autoantibodies even after diluting the sample 1:5. Since in our method, the dilution fold used for detecting antibody specificities was variable, it might be possible that antibody specificities in the previous studies were masked by warm autoantibodies or eliminated in the 1:5 diluted samples.

Although the warm autoantibodies were not completely removed by dilution, the combination with RBC phenotyping helped the identification and discrimination between autoantibodies with mimicking specificity and alloantibodies. A simple algorithm that combines the dilution technique and RBC phenotyping was introduced in our antibody identification protocol to treat patients with warm autoantibodies (Fig. 1).

When RBC transfusion is necessary for the patients with autoantibodies with mimicking specificity, the use of antigen-negative RBCs is generally considered [6]. To date, no studies on RBC transfusion to patients with autoantibodies with mimicking specificity have been performed, except for a few cases. Yun et al. [14] reported a case of one unit of e-positive packed RBCs (PRCs) that was transfused to a patient who had an autoanti-e mimicking autoantibody without inducing acute hemolytic transfusion reaction or other severe transfusion reactions. Issitt et al. [11] speculated that if the patient serum contains a mimicking autoantibody, it might not be necessary to provide antigen-negative RBCs for transfusion. In the present study, we transfused “least incompatible” RBCs to five patients having autoantibodies with apparent mimicking specificity (Fig. 1), but we did not observe any clinical symptoms indicating severe acute or delayed hemolytic transfusion reactions. Furthermore, although we discovered a high frequency of autoantibodies with mimicking specificity in the sera of patients with warm autoantibodies,
neither severe acute nor delayed hemolytic transfusion reactions have been reported after numerous “least incompatible” RBC transfusions. Thus, we suggest that autoantibodies with mimicking specificity might not cause acute or delayed hemolytic transfusion reactions.

Therefore, by using the dilution technique as screening test in the patients with warm autoantibodies, the transfusion of antigen-negative RBCs might not be mandatory when the patients have only autoantibodies with mimicking specificity; however, antigen-negative RBCs should be transfused to patients who possibly have alloantibodies.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest to this article were reported.

Acknowledgements

The authors thank Jeong-Gyoo Kim, M.T., Young-Na Park, M.T., and Kyeong-Suk Jeong, M.T., for their technical assistance.

REFERENCES

1. Leger RM and Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion 1999;39:11-6.
2. Øyen R and Angeles ML. A simple screening method to evaluate the presence of alloantibodies with concomitant warm autoantibodies. Immunohematology 1995;11:85-7.
3. Cid J, Ortin X, Pinacho A, Parra R, Contreras E, Elies E. Use of polyethylene glycol for performing autologous adsorptions. Transfusion 2005;45:694-7.
4. Branch DR and Petz LD. A new reagent (ZZAP) having multiple applications in immunohematology. Am J Clin Pathol 1982;78:161-7.
5. Branch DR and Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion 1999;39:6-10.
6. Dwyre DM, Clapper A, Heintz M, Elbert C, Strauss RG. A red blood cell autoantibody with mimicking anti-E specificity. Transfusion 2004;44:1287-92.
7. Carson TH, ed. Pretransfusion testing of patient blood. In: Standards for blood banks and transfusion services. 27th ed. Bethesda: American Association of Blood Banks, 2011:33-5.
8. Kim KH, Kim KE, Woo KS, Han JY, Kim JM, Park KU. Primary anti-D immunization by DEL red blood cells. Korean J Lab Med 2009;29:361-5.
9. Petz LD, Garratty G, eds. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Living stone, 2004:375-400.
10. Fundenberg HH, Rosenfield RE, Wasserman LR. Unusual specificity of auto-antibody in auto-immune hemolytic diseases. J Mt Sinai Hosp N Y 1958;25:324-9.
11. Issitt PD, Combs MR, Burngarner DJ, Allen J, Kirkland A, Melroy-Carawan H. Studies of antibodies in the sera of patients who have made red cell autoantibodies. Transfusion 1996;36:481-6.
12. Wheeler CA, Calhoun L, Blackall DP. Warm reactive autoantibodies: clinical and serologic correlations. Am J Clin Pathol 2004;122:680-5.
13. Garratty G. What do you do when all units are incompatible? Rev Med Inst Mex Seguro Soc 2005;43(S1):107-11.
14. Yun HK, Cho D, Chae MJ, Jeon MJ, Suh SP, Ryang DW. No hemolytic transfusion reactions in a patient with the apparent anti-e autoantibody following transfusion of packed red cells with CcDEe phenotype. Korean J Blood Transfus 2007;18:116-20.